Roles
- Professor of Clinical Medicine
-
Biography
Juan Ramos, M.D., is a Professor of Clinical Medicine in the Division of Hematology at the University of Miami Miller School of Medicine and a practicing oncologist at Sylvester Comprehensive Cancer Center. Dr. Ramos began his research career as an undergraduate at UCLA, studying cancer molecular biology and tumor suppressors in the laboratories of Richard Gaynor and Dennis Slamon. He continued his research while earning his medical degree from New Jersey Medical School–UMDNJ in 1999 and completed his residency and fellowship training at the University of Miami in 2005.
Dr. Ramos’s clinical and research focus is on virus-related malignancies, particularly HTLV-1–related adult T-cell leukemia-lymphoma and AIDS-associated cancers. He serves as principal or co-investigator on multiple peer-reviewed and NIH/NCI-funded projects and is the principal investigator of the NCI-sponsored AIDS Malignancy Consortium site in Miami. He has also led NCI-funded projects on HTLV-1 and the University of Miami–Argentina U54 consortium.
His research has been widely presented at national and international conferences and published in peer-reviewed journals. Dr. Ramos is also deeply committed to education, mentoring medical and undergraduate students, residents, and fellows in hematology-oncology training programs. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Research Interests
I devote my academic career to the study of viral related cancers in the clinic and laboratory. Much of this effort relates to translational projects on HTLV-1 related adult T-cell leukemia-lymphoma and AIDS-associated malignancies. i have carried out and continue to develop bench-to-clinic therapies for HTLV-1 and HIV related cancers. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 10 clinical trials.
-
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
This study is being done to develop better treatments for plasmablastic lymphoma for HIV-positive and HIV-negative people. The purpose of this study is to test the safety of daratumumab, a drug added to the standard lymphoma treatment.
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase I
- Enrollment Status: Open
-
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
To study the role of anticancer or antiviral drugs in viral associated malignancies. The proposed study is based upon recent observations made at the University of Miami. Lymphomas and other cancers that arise in immune compromised individuals (AIDS, posttransplant, subtropical areas) are frequently associated with cancer causing viruses (Epstein Barr Virus [EBV, Human T lymphotropic Virus Type I [HTLVI, Hepatitis B and C [HBV, HCV, Human Herpes Virus Type 8 [HHV8). We have found that certain types of these cancers are extremely sensitive to antiviral or anticancer agents such as Azidothymidine (AZT). Long term remissions have been obtained in some patients with otherwise fatal tumors when treated with intravenous antivirals. Limited studies on commercially available tumor cell lines have demonstrated that AZT specifically induces apoptosis (programmed cell death) in some of these tumors. In order to characterize which viral associated cancers are likely to be sensitive to this therapy, we need to study tumor cells that are derived directly from patients as commercially available lines are not reliable due to biologic changes induced by longterm culture. By establishing which tumor types are sensitive to antiviral therapy, we can design more specific, targeted therapies. This is potentially a major breakthrough in the treatment of aggressive viral associated malignancies.
- Principal Investigator: Juan Carlos Ramos
- Study Phase: N/A
- Enrollment Status: Open
-
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase 1
- Enrollment Status: Not Accepting
-
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
- Principal Investigator: Juan Carlos Ramos
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed